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Introduction: Radon exposure has been classified as the second 
cause of lung cancer, after tobacco, and the first in never smokers. 
GSTM1 and GSTT1 genes deletion increase the risk of lung cancer. 
We aim to know whether the risk of lung cancer because of residen-
tial radon is modulated by these genetic polymorphisms.
Methods: Hospital-based, case-control study where cases had 
confirmed lung cancer. Cases and controls did not have previous 
neoplasm and were older than 30. Controls attended hospital for 
noncomplex surgery. We analyzed the results for the whole sample 
and separately for never/light smokers and moderate/heavy smokers.
Results: Seven-hundred and ninety-two participants were analyzed. 
GSTM1 and GSTT1 deletion conferred an odds ratio (OR) of 1.38 
(95% confidence interval [CI] 0.93–2.04) and 1.13 (95% CI 0.70–
1.82), respectively. Individuals with GSTM1 present and residen-
tial radon concentrations higher than 148 Bq/m3 had an OR of 1.48 
(95% CI 0.73–3.00), whereas those with GSTM1 deleted had an OR 
of 2.64 (95% CI 1.18–5.91) when compared with participants with 
GSTM1 present and radon concentrations below 50 Bq/m3. Similar 
results were observed for GSTT1 deletion. These results were basi-
cally the same for the moderate/heavy smokers’ subgroup.
Conclusions: The absence of GSTM1 and GSTT1 genes increases 
the risk of lung cancer because of radon exposure. These genes might 
modulate the carcinogenic pathway of alpha radiation. Further stud-
ies are warranted analyzing this association in never smokers.
Key Words: Lung neoplasms, Residential radon, Genetic 
susceptibility
(J Thorac Oncol. 2014;9: 1073–1080)
Lung cancer is a major health problem in developed coun-tries. It is the leading cause of cancer death in males and 
females in the United States, according to recent data. Lung 
cancer mortality in females doubles that caused by breast can-
cer.1 Survival has hardly improved in the last 30 years, with a 
13–17% 5-year survival rate.1,2
Lung cancer incidence in Spanish males has an inter-
mediate position regarding other European Union countries. 
Standardized incidence rate (2012 estimations) was 66.3 
cases/100,000 persons-year in Europe and 76.8 in Spain. 
Lung cancer incidence in females was one of the lowest (26.1 
cases/100,000 persons-year in Europe versus 15.7 in Spain). 
Lung cancer is the second cause of mortality and the first 
cause of cancer death in Spanish males.3
Radon is the second cause of lung cancer after active 
smoking and the leading cause in never smokers.4 The United 
States Environmental Protection Agency (USEPA)5 and the 
World Health Organization4 have published recommendations 
to aware citizens on radon exposure hazards.
Radon emits radiation in form of α-particles that dam-
age lung epithelia by generating oxygen-anions and hydrogen 
that produce mutations and other DNA lesions.6 Neighboring 
nonirradiated cells may also be damaged through a “bystander 
effect,” whereby cellular signaling from an irradiated cell may 
induce oxidative stress in adjacent but nonirradiated cells.7
Genetic polymorphisms on genes participating in detox-
ification processes of environmental carcinogens can modu-
late lung cancer risk. Animal models suggest that several gene 
polymorphisms may cooperate in increasing the individual 
risk of lung cancer.8
Polycyclic aromatic hydrocarbons and aromatic amines 
are classes of compounds that cause cancer in humans. 
Microsomal epoxide hydrolase 1 (EPHX1) plays an impor-
tant role in both the activation and detoxification of polycyclic 
aromatic hydrocarbons and aromatic amines. A meta-analy-
sis has indicated that in white population, the high activity 
variant genotype of EPHX1 polymorphisms at exon 4 was 
associated with a modest increase in the risk of lung cancer.9 
Cytosolic glutathione S-transferase family are a large family 





Alberto Ruano-Ravina, PharmD, MPH, PhD,*† Marco F. Pereyra, MD,‡  
Marta Tojo Castro, MSc, PhD,§║ Mónica Pérez-Ríos, PharmD, MPH, PhD,*†  
José Abal-Arca, MD,¶ and Juan Miguel Barros-Dios, MD, MPH, PhD*†#
*Department of Preventive Medicine and Public Health, University of 
Santiago de Compostela, Santiago de Compostela, A Coruña; †CIBER 
de Epidemiología y Salud Pública, CIBERESP; ‡Service of Neumology, 
Clinic University Hospital; §Department of Physiology, School of 
Medicine-CIMUS-Instituto de Investigaciones Sanitarias, University 
of Santiago de Compostela, Santiago de Compostela, A Coruña, Spain; 
║Metabolic Research Laboratories, Department of Obstetrics and 
Gynaecology, University of Cambridge, Cambridge, United Kingdom; 
¶Service of Neumology, Ourense Hospital Complex, Ourense; and 
#Service of Preventive Medicine, Clinic University Hospital Complex of 
Santiago de Compostela, A Coruña, Spain.
Disclosure: This research has received competitive funding by the Instituto 
de Salud Carlos III, Ministry of Science and Innovation of Spain, grant 
number, PI031248. All other authors declare no conflict of interest.
Address for correspondence: Alberto Ruano-Ravina, PharmD, MPH, 
PhD, Department of Preventive Medicine and Public Health, School of 
Medicine, C/ San Francisco s/n, University of Santiago de Compostela, 
15782 Santiago de Compostela, A Coruña, Spain. E-mail: alberto.
ruano@usc.es
Original Article
1074 Copyright © 2014 by the International Association for the Study of Lung Cancer
Ruano-Ravina et al. Journal of Thoracic Oncology ®  •  Volume 9, Number 8, August 2014
of isozymes involved in detoxification of many electrophilic 
substrates. The mu (GSTM1) and theta (GSTT1) members 
are susceptibility genes because of their ability to regulate the 
conjugation of carcinogenic compounds to excretable hydro-
philic metabolites.10 GSTM1 and GSTT1 genes are deleted 
among 50% and 20% of Caucasians, respectively,11 and this 
results in the lack of an active enzyme.10 Meta-analyses have 
indicated that the carriers of GSTM1 null or GSTT1 null gen-
otypes have a higher risk of developing lung cancer compared 
with carriers of at least one functional allele.12,13
Despite the literature analyzing the effect of many 
genetic polymorphisms on the risk of lung cancer and their 
interaction with tobacco consumption, there are very few 
studies assessing residential radon exposure in combination 
with different variants of susceptibility genes. We have found 
only one case-only study14 providing evidence of a GSTM1-
radon interaction on the risk of lung cancer. There is also no 
information regarding whether the possible effect of radon 
exposure modulated by these genes could be different for 
never/light smokers or moderate/heavy smokers.
The aim of the present study is to assess, to our knowl-
edge for the first time through a case-control study, whether 
there is any effect modification between polymorphisms in 
GSTM1, GSTT1, and EPHX1 genes and residential radon 
exposure on the risk of lung cancer. A secondary objective is 
to assess whether this effect is different for never/light smok-
ers or moderate/heavy smokers.
MATERIALS AND METHODS
Design, Subjects, and Settings
A hospital-based, case-control study was conducted in 
Northwest Spain (Galicia) between 2004 and 2008. Galicia 
is characterized for having high indoor radon concentra-
tions because of the granitic nature of the earth crust.15,16 
Approximately, 19–21% of all dwellings are above the USEPA 
action level. This fact places Galician population on a natural 
experiment where research on radon-related health effects can 
take advantage. A further advantage is that previous studies 
have demonstrated that Galician population has low mobility. 
The median of years living in the same residence is 30,17 and 
therefore radon effects can be attributed easier than in other 
populations.
We recruited cases and controls at two Galician hospitals 
with full capacity to diagnose and treat lung cancer. The par-
ticipating hospitals were the Santiago de Compostela Clinic 
University Hospital and the Ourense Hospital Complex. Both 
had to be older than 30 and should have lived at least 5 years in 
their current residence. Individuals with previous cancer were 
excluded. Cases had an anatomopathologically confirmed 
lung cancer and were recruited through consecutive sampling. 
Cases were identified through checking at least twice per week 
the databases of the Pathologic Anatomy Department. They 
were interviewed immediately after diagnosis. Controls were 
recruited from individuals attending hospital for noncomplex 
surgery unrelated with tobacco consumption. We selected 
controls with this characteristic to avoid selection bias in order 
that controls can represent adequately tobacco consumption of 
the general population and not over represent it. Two days per 
week one researcher recruited controls from the presurgery 
unit of both participating hospitals that fulfilled the inclusion 
criteria. More than 90% of the controls underwent the follow-
ing surgeries: orthopedic surgery, cataract surgery, or surgery 
for inguinal hernias. We did a frequency-based sampling of 
controls regarding cases on age and gender to guarantee that 
both were comparable for these two variables. The study pro-
tocol was approved by the Galician Clinical Research Ethics 
Committee (REF 2004/108) and informed written consent 
was obtained from all participants. The results of residential 
radon exposure on lung cancer have been published recently.17
Information Retrieval
All participants were interviewed by trained research-
ers using a detailed questionnaire with special attention on 
lifestyle habits. We collected detailed information regarding 
tobacco consumption. The questions on tobacco consumption 
were directed to the etiologic period, that is, 30 to 5 years pre-
viously to the time of the interview. For the purpose of this 
study, tobacco exposure was classified in four categories, 
never smokers, and smokers in tertiles according to their life-
time tobacco consumption: light smokers (1–33 packs/yr), 
moderate smokers (34–66 packs/yr) and heavy smokers (>66 
packs/yr). We used these categories for adjusting the results 
by tobacco consumption.
Radon Measurements
A radon technician placed a detector in the participants’ 
homes. The devices were of the alpha-track type (Radosys) 
and were away from doors, windows, or electrical devices 
and between 60 and 180 cm off the floor. The detectors were 
placed for a minimum of 6 months and radon concentrations 
were determined at the Galician Radon Laboratory at the 
Santiago de Compostela Clinic University Hospital. Seasonal 
adjustment was taken into account when the detectors were 
revealed. Quality controls are conducted periodically and 
our laboratory has been certified through intercomparison 
tests organized by the University of Cantabria with excellent 
results.18
Laboratory Methods
Total blood was collected in 5 ml EDTA tubes and 
was transferred to FTA classic cards (Whatman, Maidstone, 
United Kingdom). FTA cards were left to dry for a minimum 
of two hours and then stored in foil envelopes with a desic-
cant at room temperature. Before DNA extraction, a disc with 
a diameter of 2 mm was cut out from each of the FTA cards 
using a Harris Micro Punch tool and was placed into a clean 
Eppendorf. Discs were washed twice with FTA Purification 
Reagent and vortexed. Then, samples were washed twice in 
TRIS-EDTA (10 mM Tris, 0.1 mM EDTA, pH8) and were left 
to air dry for one hour.
Polymorphic deletion of the GSTM1 was determined 
by polymerase chain reaction (PCR) using β-interferon as an 
internal control. PCR conditions, including primer sequences 
were carried out following the protocol described previously 
by Khedhaier et al.19 PCR products were amplified on the disc. 
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GSTs deletion and exon 4 EPHX single nucleotide polymor-
phisms SNP (rs2234922) was determined using MassARRAY 
SNP genotyping system (Sequenom Inc, San Diego, CA), 
according to manufacturer’s instructions. The principles of 
this method are detailed in Buetow et al.20 SNP genotyping 
services were provided by the Spanish “Centro Nacional de 
Genotipado” CeGen-ISCIII (www.cegen.org).
Statistical Analysis
A bivariate descriptive analysis was conducted to deter-
mine the distribution of the study variables according to the 
case or control status. Then, an unconditional logistic regres-
sion was performed, where the dependent variable was the 
case or control status and the independent variables were the 
presence or absence of the genes GSTM1, GSTT1, or EPHX1 
polymorphisms, and indoor radon exposure (divided into 
four categories: <50, 50–100, 101–147, and >147 Bq/m3). 
As adjustment variables, we included age (continuous), gen-
der, and tobacco consumption (in four categories). We per-
formed the same analysis but stratifying the sample in never/
light smokers (those who had smoked 10 or less pack-years 
in lifetime) and in moderate/heavy smokers (> 10 pack-years 
during lifetime). We did this analysis to assess possible differ-
ences on the effect of each gene due to tobacco consumption. 
We included light smoking cases with never smokers because 
there were only five light smokers.
To assess whether genetic polymorphisms modified the 
effect of residential radon exposure on lung cancer, we cre-
ated three variables using syntaxes that combined simultane-
ously each gene variant with radon exposure. We therefore 
created a variable combining GSTM1 and radon exposure 
with six categories (GSTM1 present or null and radon expo-
sure in 3 categories, being the reference category individu-
als with the gene present and exposed to <50 Bq/m3). The 
same was done for GSTT1 gene and radon exposure. For 
EPHX1, a variable with six categories was created (two 
for EPHX1 gene, wild-type and G carrier (AG or GG) and 
three categories for radon exposure). We decided to join G 
carrier categories because there were only 29 individuals 
with the GG heterozygous form. The results of these mod-
els are presented adjusted by tobacco consumption, age, and 
gender. To explore the possibility of residual confounding 
because of tobacco consumption and to compare results for 
the whole sample and for moderate/heavy smokers, we did 
the same analysis only including them (>10 pack-years dur-
ing lifetime). The results were adjusted by gender, age, and 
tobacco consumption. Because of the low number of never/
light smoking cases (n = 39) this analysis was not done for 
this subgroup. We also assessed the possibility of an additive 
synergism between radon exposure (two categories with the 
cut point in 148 Bq/m3) and the genes assessed (classified 
as present, absent, or G carrier) using the method proposed 
by Hosmer and Lemeshow.21 Results are expressed as odds 
ratios (OR) with their 95% confidence intervals. Analyses 
were conducted with SPSS version 17.
RESULTS
Nine-hundred and ninety individuals were initially 
included, 442 cases and 548 controls. The participation rates 
were high, 90% of all contacted cases and higher than 75% 
of all contacted controls. Eight-hundred and sixty-two partici-
pants (87%) of the 990 initially included, 349 (79.0%) cases 
and 513 (93.6%) controls, had complete radon measurements, 
but 70 individuals did not have a tobacco history allowing 
for the calculation of lifetime tobacco consumption, leaving 
792 individuals. Of them, 716, 695, and 668 individuals had 
genotyping results for GSTM1, GSTT1, and EPHX1 genes, 
respectively. Figure 1 displays the participation rate and the 
individuals available for the multivariate analysis.
Table 1 shows the sample description broken down by 
case and control status. Age and gender distribution among 
cases and controls was similar whereas tobacco consumption 
was higher for cases compared with controls. The tobacco 
categories shown in the table are the same used for the sub-
group analysis that considers never/light smokers and mod-
erate/heavy smokers, and it can be observed the low number 
of light smoking cases. There were 38 cases and 262 never/
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heavy smoking controls. Indoor radon concentration was 
slightly higher for cases versus controls, especially in those 
exposed to concentrations higher than 148 Bq/m3; 20% of 
cases versus 15% of controls surpassed 148 Bq/m3 (USEPA 
action level).
Table 2 presents the effect of the absence of GSTM1 
and GSTT1 genes and polymorphism in exon 4 of the EPHX1 
gene. GSTM1 is absent in 44.2% of cases versus 39.8% 
of controls. For the GSTT1 gene, these figures are 21% for 
cases versus 19.2% in controls. The EPHX1 heterozygous 
was found in 33% of cases versus 34.8% of controls and the 
EPHX1 homozygous in 3.5% of cases versus 4.5% of con-
trols. Although it seems to be no association with lung cancer 
for GSTT1 absence and EPHX1 exon 4 polymorphism, for 
the GSTM1 deletion, there is a marginally significant asso-
ciation, with an OR of 1.38 (95% CI 0.93–2.04). Results are 
adjusted by all the genes analyzed and also by age, gender, 
tobacco consumption, and residential radon concentration. 
When we analyze exclusively never and light smoking indi-
viduals, we can observe a higher risk of lung cancer when 
GSTM1 and GSTT1 are absent, with GSTT1 deletion having 
a marginally statistical effect. Heterozygous AG individuals 
for EPHX1 exon 4 polymorphisms show a protective effect 
(n = five AG cases). The results for moderate/heavy smokers 
are quite similar to the whole sample, specially for EPHX1 
exon 4 polymorphisms. For GSTM1, we observe and OR of 
1.15 (95% CI 0.75–1.75) and for GSTT1, the results are not 
statistically significant.
The effect on lung cancer risk of the different levels of 
residential radon combined with the presence or absence of 
GSTM1 gene is showed in Table 3. It can be observed that 
for the same radon concentrations the risk of lung cancer 
is higher when GSTM1 is deleted and also that lung can-
cer risk increases when radon concentration increases. The 
OR for individuals exposed to indoor radon concentrations 
higher than 148 Bq/m3 with GSTM1 present is 1.52 (95% CI 
0.75–3.06) while for the same radon exposure when the gene 
is deleted is 2.64 (95% CI 1.18–5.91). No additive interac-
tion was observed for GSTM1 deletion and radon exposure. 
When the analysis is restricted to moderate/heavy smokers, 
the results are similar to the whole sample. Lung cancer risks 
are higher for individuals lacking GSTM1 and exposed to 
higher radon concentrations than for individuals with the gene 







p Valuen (%) n (%)
Age
  ≤50 16 (6.3) 43 (9.3) > 0.05a
  51–70 138 (54.1) 285 (61.8)
  >70 101 (39.6) 133 (28.9)
Gender
  Female 34 (13.3) 59 (12.8 > 0.05a
  Male 221 (86.7) 402 (87.2)
Tobacco consumption
  Never smokers 33 (12.9) 209 (45.3) <0.05a
  Light smokers (1–10 pack-years) 5 (2.0) 53 (11.5)
  Moderate smokers (11–66 pack-years) 109 (42.7) 158 (44.3)
  Heavy smokers (>66 pack-years) 108 (42.4) 41 (8.9)
Indoor radon exposure, Bq/m3
  ≤ 50 68 (26.7) 175 (38.0) <0.05a
  51–100 93 (36.5) 150 (32.5)
  101–147 43 (16.8) 67 (14.5)
  ≥148 51 (20..0) 69 (15.0)
Years living in the measured dwelling >0.05b
  Median 30 30





Crude OR  
(95% CI)
Adjusted ORb,c  
(95% CI)
Adjusted ORd  
(95% CI) Restricted to 
Never and Light Smokers 
(≤ 10 Pack-Years Over 
Lifetime)
Adjusted ORe (95% CI) 
Restricted to Moderate/ 
Heavy Smokers  
(> 10 Pack-Years During 
Lifetime)
GSTM1 158 291 1 (—) 1 (—) 1 (—) 1 (—)
GSTM1 null 125 192 1.15 (0.83–1.59) 1.38 (0.93–2.04) 1.72 (0.73–4.03) 1.15 (0.75–1.75)
GSTT1 211 384 1 (—) 1 (—) 1 (—) 1 (—)
GSTT1 null 56 91 1.10 (0.74–1.63) 1.13 (0.70–1.82) 2.42 (0.91–6.45) 0.85 (0.51–1.42)
EPHX1 exon 4
  Wild-type (AA) 166 272 1 (—) 1 (—) 1 (—) 1 (—)
  Heterozygous (AG) 86 156 0.91 (0.64–1.28) 0.83 (0.54–1.25) 0.33 (0.11–0.99) 0.91 (0.59–1.41)
  Mutant (GG) 9 20 0.78 (0.35–1.76) 0.65 (0.24–1.79) 0.49 (0.05–5.02) 0.72 (0.25–2.05)
a The number of cases and controls is the used for the crude regressions.
bAdjusted for age, gender, tobacco consumption in four categories, indoor radon exposure in four categories and for all polymorphisms.
cThe total number of individuals in the adjusted regression is 660: 233 cases and 427 controls.
dIncludes 33 cases and 243 never smoking controls or who had smoked 10 pack-years or less in lifetime. Adjusted for age, gender, indoor radon exposure in four categories and 
for all polymorphisms.
eIncludes 200 cases and 184 controls who smoked more than 10 pack-years in lifetime. Adjusted for age, gender, indoor radon exposure in four categories and for all polymorphisms.
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Table 4 shows the effect of GSTT1 deletion for the dif-
ferent categories of residential radon exposure on the risk of 
lung cancer. The risk of lung cancer is higher when GSTT1 
is absent for radon concentrations between 50 and 148 Bq/
m3. The odds ratio changes for radon exposures higher than 
148 Bq/m3. The OR for GSTT1 deleted is 1.10 (95% CI 
0.39–3.08), whereas when the gene is present is 1.98 (95% 
CI 1.06–3.70). There were only eight cases and 16 controls 
with radon exposure higher than 148 Bq/m3 and GSTT1 
absent. No additive interaction was observed between radon 
exposure and GSTT1 gene. There are little differences with 
the former results when the analysis is restricted to moder-
ate/heavy smokers.
Table 5 shows the effect of EPHX1 exon 4 polymor-
phism combined with different residential radon concentra-
tions. The higher OR are observed for the wild-type when 
radon concentration is between 50 and 148 Bq/m3, and for the 
G form (AG or GG) with the highest radon concentrations, 
with an OR of 3.05 (95% CI 1.25–7.43). No additive interac-
tion was observed between radon exposure and EPHX1 exon 
4 polymorphism. The results are essentially the same when the 
analysis is restricted to moderate/heavy smokers.
DISCUSSION
To our knowledge, this is the first study with a case-con-
trol design assessing multiple genetic polymorphisms in com-
bination with residential radon exposure on the risk of lung 
cancer. We have observed that lung cancer risk for the same 
indoor radon concentration is higher when GSTM1 or GSTT1 
genes are absent. No clear effect is evident for EPHX1 poly-
morphisms for different radon concentrations on the risk of 
lung cancer. When the analysis is restricted to moderate/heavy 
smokers (> 10 pack-years during lifetime) the results hardly 
differ when compared with the results of the whole sample. 
This gene-environment interaction is evident at radon concen-
trations below the action level recommended by the USEPA.
At first sight, it seems that the results observed for the 
analyzed genes could be driven by tobacco consumption. 
Table 2 shows that there are differences when never/light 
smokers and moderate/heavy smokers are analyzed sepa-
rately. Nevertheless, for GSTM1 deletion, we observe a posi-
tive association for both categories, and the lowest confidence 
interval is very similar among them. We have to highlight 
that these results are adjusted by many covariables (gender, 
age, indoor radon exposure, and all studied genes) and that 
TABLE 3.  Residential Radon Exposure and GSTM1 Effect on Lung Cancer Risk
Indoor Radon  
Exposure (Bq/m3)
Restricted to Moderate/Heavy Smokers  
(> 10 Pack-Years During Lifetime)
GSTM1 (Cases, Controls); ORa,b (95% CI) GSTM1 (cases, controls); ORa,c (95% CI)
Present Null Present Null
0–50 41, 95 27, 80 33, 44 23, 38
1 (—) 0.87 (0.44–1.70) 1 (—) 0.95 (0.45–2.00)
51–147 77, 138  58,79 69, 55 48, 28
1.39 (0.80–2.40) 2.32 (1.26–4.26) 1.74 (0.93–3.24) 2.70 (1.33–5.48)
>147 28, 46 24, 23 25, 21 19, 13
1.52 (0.75–3.06) 2.64 (1.18–5.91) 2.16 (0.97–4.82) 2.41 (0.97–5.99)
aAdjusted for age, sex and tobacco consumption.
bTotal sample (n = 716).
cn = 416.
TABLE 4.  Residential Radon Exposure and GSTT1 Effect on Lung Cancer Risk
Indoor Radon  
Exposure (Bq/m3)
GSTT1 (Cases, Controls); ORa,b (95% CI)
Restricted to Moderate/Heavy Smokers  
(> 10 Pack-Years During Lifetime)
GSTT1 (Cases, Controls); ORa (95% CI)
Present Null Present Null
0–50 55, 130 10, 43 48, 61 7, 19
1 (—) 0.51 (0.21–1.22) 1 (—) 0.43 (0.16–1.19)
51–147 93, 183 35, 29 81, 69 30, 12
1.34 (0.83–2.17) 3.70 (1.77–7.74) 1.53 (0.90–2.62) 3.00 (1.31–6.90)
>147 41, 52 8, 16 35, 24 6, 9
1.98 (1.06–3.70) 1.10 (0.39–3.08) 2.22 (1.10–4.49) 0.96 (0.30–3.08)
aAdjusted for age, sex and tobacco consumption.
bTotal sample (n = 695).
cn = 401.
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there are only 33 never/light smoking cases included in this 
analysis. This fact produces wider confidence intervals for 
the category of never/light smokers than for ever-smokers 
and therefore imprecise results. A different effect for never/
light and moderate/heavy smokers appears to be present for 
GSTT1 deletion, although in this case there are only 10 never/
light smoking cases with the gene absent. These low numbers 
do not allow establishing a consistent conclusion regarding 
a different effect driven by tobacco consumption. The same 
explanation may apply to EPHX1 polymorphisms.
Regarding the possible differential effect of radon 
exposure on lung cancer risk depending on the presence or 
absence of the analyzed genes, it can be observed (Table 3) 
that: (1) lung cancer risk increases with radon exposure when 
GSTM1 is present or absent, (2) the risk appears to be higher 
when GSTM1 gene is deleted, for all radon exposure catego-
ries and (3) the risk is quite similar for the whole sample and 
for moderate/heavy smokers. The same interpretation can 
be done for GSTT1 deletion and EPHX1 polymorphisms, 
although it is important to highlight the inconsistent results 
observed for GSTT1 null individuals exposed to the highest 
radon concentrations. There is no risk of lung cancer but this 
category includes only six cases and nine controls, a number 
much lower than the number of individuals existing for other 
categories. The following exposure category has 42 individu-
als, close to three times higher. A similar explanation could be 
given for EPHX1 wild-type individuals exposed to more than 
147 Bq/m3, although in this case the number of participants is 
also low for G carriers. It is important to underline that the dif-
ferences on lung cancer risk between wild-type and G carriers 
persist for those exposed to more than 147 Bq/m3.
A previous study from Bonner et al.14 supports our 
observation for the GSMT1 null genotype. A plausible expla-
nation is based on the knowledge that high-linear energy 
transfer α-particle, like those emitted by inhaled radon, causes 
DNA damage by the metabolic generation of reactive oxygen 
species (ROS),6 which in turn, in the absence of regulatory 
enzymes such as glutathione S-transferase, induce signaling 
pathways that could preclude cancer appearance.22
Another important issue is the fact that the gene-envi-
ronment interaction was mainly present at relatively low 
indoor radon concentrations. Taioli et al.23 defined a low expo-
sure-gene effect when a greater degree of gene-environment 
interaction appears at lower doses of exposure (the interaction 
follow an inverse dose function). Vineis et al.24 also mention 
a exposure-gene effect, stating that there is a genetic hetero-
geneity, with a “depletion of susceptibles” at low dose lev-
els, resulting in decreasing risk with increasing exposure. 
This possibility could explain the results observed for GSTT1 
absence with high residential radon concentrations, opposite 
to expected.
A special case of interaction between radiation and gene 
polymorphisms is present in cytotoxicity caused by radiation 
therapy. When cells are exposed to ionizing radiation, decom-
position occurs, through which a variety of ROS are generated.25 
Of all agents used, cyclophosphamide particularly results in 
generation of ROS, which was demonstrated by rodent data.26 
Under radiation therapy, individuals with GSTM1 null geno-
types would experience a higher effective dose of chemotherapy 
and/or more reactive oxidant damage to tumor tissue. Therapy 
might then be more effective in GSTM1 null patients, as has 
been reported for GSTM1 null breast cancer patients.27
There is more evidence on the gene-environment inter-
action. Goto et al.28 have proposed a model in which smokers 
with GSTM1 deletion would produce more carcinogen-DNA 
adducts in lung tissue and would develop mutations on genes 
involved in tumor growth and metastasis. Because of the pres-
ence of these mutations, GSTM1 null patients would present 
more aggressive tumor biology and poorer survival.29
Gamma radiation is another type of ionizing radiation, 
with a well described metabolism and genotoxicity. EPHX1 
and GSTs play an important role in the .detoxification of elec-
trophiles and oxidative stress. Vineis et al.24 assessed the dose-
dependent effect of genetic polymorphisms (EPHX, GSTP1, 
GSTM1, and GSTT1) in biotransforming on the induced 
genotoxicity by analyzing peripheral blood mononuclear cells 
from 20 individuals who were exposed to gamma radiation. 
They conclude that the influence of genetic polymorphisms 
of enzymes involved in DNA repair on induced genotoxicity 
depends on exposure dose.
Marcon et al.30 carried out a mutagen sensitivity assay 
to investigate the role of inherited and acquired factors on 
TABLE 5.  Residential Radon Exposure and EPHX1 Exon 4 Polymorphism Effect on Lung Cancer Risk
Indoor Radon  
Exposure (Bq/m3)
Restricted to Moderate/Heavy Smokers  
(> 10 Pack-Years During Lifetime)
EPHX1 (Cases, Controls); ORa,b (95% CI) EPHX1 (Cases, Controls); ORa,c (95% CI)
Wild-Type (AA) G Carrier (AG and GG) Wild-Type (AA) G carrier (AG and GG)
0–50 40, 97 20, 68
0.58 (0.28–1.21)
33, 37 18, 38
1 (—) 1 (—) 0.48 (0.21–1.06)
51–147 82, 116 45, 83
1,27 (0.68–2.37)
69, 45 42, 32
1.90 (1.07–3.35) 1.66 (0.87–3.17) 1.59 (0.79–3.21)
>147 28, 49 21, 19 21, 24 20, 9
1.26 (0.62–2.55) 3.05 (1.25–7.43) 1.02 (0.45–2.32) 3.44 (1.29–9. 17)
aAdjusted for age, sex, and tobacco consumption.
bTotal sample (n = 668).
cn = 388.
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individual variation in DNA repair capacity. They irradiated 
fresh blood samples with gamma rays and detected sponta-
neous and induced structural chromosomal aberrations in 
lymphocytes 48 h after irradiation. They obtained a higher 
frequency of radiation-induced DNA aberrations in GSTM1 
present individuals compared with GSTM1 null subjects. 
They concluded that a modulator effect of GSTM1 genotype 
on the individual DNA repair capacity is possibly related to 
the higher expression of enzymes involved in the repair of oxi-
dative DNA damage in GSTM1 null subjects.
The relation between genotypes and chromosomic aberra-
tions was also assessed in humans under irradiation. One study 
describes that the frequencies of chromosomic aberrations in a 
group of workers at Chernobyl Nuclear Station after the acci-
dent depend on some genotypes presented by participants.31 
Chromosomic aberrations in these workers were reduced in 
subjects with GSTM1 and GSTT1 null. However, the authors 
concluded that the elevated level of chromosomic aberrations 
is characteristic of an elevated level of spontaneous aberrations, 
and it does not completely correspond to genotypes.
Sakly et al.32 assessed occupationally induced chro-
mosomic damage in a large population of hospital work-
ers exposed to low doses of ionizing radiation. GSTM1 and 
GSTT1 were postulated to be involved in the detoxification 
of endogenous and exogenous genotoxicants. They concluded 
that GSTM1 and GSTT1 polymorphisms do not modify sig-
nificantly the genotoxic potential of ionizing radiation.
Despite the available evidence showing the implication 
of GSTM1, GSTT1, and EPHX1 genes on the metabolic path-
way on detoxification of ROS, the data are inconclusive. More 
biological support is needed to fully understand the interac-
tion between ionizing radiation, genetic polymorphisms, and 
lung cancer risk because of residential radon exposure.
The study area is a radon prone region and this fact 
facilitates the analysis of a dose-response effect for radon 
exposure on lung cancer and also the interaction with suscep-
tibility genes. In other settings, the analysis of interaction is 
not possible because of the homogeneity of radon exposure 
(low concentrations). Approximately 50% of the Galician 
population lives in the countryside in single detached houses. 
Because radon is denser than air, radon concentrations tend 
to be higher in isolated houses than in blocks of apartments. 
Cases and controls represent adequately the general popula-
tion because there is universal health coverage provided by the 
Regional Government. Close to 100% of lung cancer cases are 
diagnosed in the public health system and the same happens 
for the surgical interventions performed in controls. A similar 
study but with a smaller sample size (n = 319) and not includ-
ing radon measurements obtained similar results for the effect 
of GSTM1 and GSTT1 deletion on lung cancer risk.33 This 
study included individuals with similar characteristics to those 
included in the present study.
The present study has important limitations. The sample 
size was not high enough to study in depth the effect of some 
polymorphisms. This was noted for the GSTT1 null and par-
ticularly for the EPHX1 exon 4 polymorphism as has been 
mentioned before. Prevalence for homozygous EPHX1 in cases 
was 3.4% versus 4.4% in controls, that are very close to the 
3.2% prevalence of this polymorphism observed in Caucasians. 
Likewise, the prevalence for GSTT1 null in cases was 21% ver-
sus 19.2% in controls, that is very close to the 20% prevalence 
of this polymorphism in Caucasians.11 Not all individuals had 
information available on radon exposure, tobacco consumption 
or genetic polymorphisms. Although this fact might increase 
the possibility of a selection bias, we think that this bias is not 
present. Individuals with data absent on those variables are quite 
similar to the individuals finally included in the analysis (data 
not shown). We have not been able to analyze properly the effect 
of susceptibility genes in never and light smokers (≤10 pack-
years) and the possible differential effect for radon exposure in 
this subsample because of the low number of cases in this cat-
egory (n = 33). Nevertheless, when we analyzed the possibility 
of a potential residual confounding because of tobacco con-
sumption, we have observed that the results are very similar for 
moderate/heavy smokers compared with the results observed for 
the whole sample. A last limitation is that Galician population 
race is homogeneous (Caucasian whites) and therefore we can-
not analyze the effect of these polymorphisms in different races.
Our study has also some advantages. The number of 
covariables taken into account in the analysis has been high. 
Results are adjusted by age, gender, tobacco consumption, 
three genetic polymorphisms, and also radon has been taken 
into account. The median number of years that cases and con-
trols have been living in the same dwelling is very high, 30 
years for both. Finally, all cases had a confirmed lung cancer 
diagnosis and were interviewed immediately after diagnosis 
to avoid recall bias. Controls were selected from nontobacco 
related surgery to minimize selection bias.
There is some possibility that the results observed could 
pose an impact. Many individuals could be interested in know-
ing whether they have a higher risk of lung cancer because of 
radon exposure related with the assessed polymorphisms. The 
existence of a possible effect modification of radon exposure 
conferred by susceptibility genes could increase radon aware-
ness in population, especially in individuals living in radon 
prone areas.
To conclude, our study supports the hypothesis that the 
absence of GSTM1 and GSTT1 genes increases the risk of 
lung cancer in subjects exposed to residential radon, indicat-
ing that these genes can modulate the effect of environmental 
exposures. More studies focused exclusively in never smokers 
are warranted to know whether this effect persists in this sub-
group of lung cancer cases. This research can provide some 
clues on the biology of radon-induced lung cancer, although 
the biological pathways should be studied taking into account 
more susceptibility genes along with genes participating in 
the regulation of the cell cycle.
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